Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients.
about
Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal typeCD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal typeFirst-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: An updated analysis with long-term follow-upIncreased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapyPost-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphomaHistological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal typeRadiation dose reduction for patients with extranodal NK/T-cell lymphoma with complete response after initial induction chemotherapy.PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type.A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy.The significance of combining radiotherapy with chemotherapy for early stage extranodal natural killer/T-cell lymphoma, nasal type: a systematic review and meta-analysis.Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type.Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma.Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma.Red blood cell distribution width as a predictor of survival in nasal-type, extranodal natural killer/T-cell lymphoma.Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma.Prophylactic cervical lymph node irradiation provides no benefit for patients of stage IE extranodal natural killer/T cell lymphoma, nasal type.Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor.
P2860
Q33798600-DFE5A95D-1349-4B5E-BAE2-7FC405043301Q34650606-4F36E129-20D8-4056-9B02-831359B3BCDDQ35871234-7A9E36B0-D6B4-448E-8991-B3DCDB222B24Q36078298-CEAF8CF4-5E40-45AF-907E-07FFD88772B2Q36557585-F98A0ECF-3AB1-4AC4-A667-32C5E1487AB6Q36760583-63C98360-0C25-42F6-9E85-7A2DEBE35DF8Q37108162-4008C931-7614-4B94-9D36-EB0C85DD55A0Q37301336-669AF3AC-9DFC-42D4-B65C-DEC6985D79BFQ37340738-616400EC-1AA1-4A5E-9C7E-74ED4BE6A854Q37738081-E49F1B45-55B9-42DC-9357-7C90B583E163Q37746330-4A442818-E96E-4BA7-95FA-6AFC4B3D2935Q38124057-786CA2C8-419A-4D0B-990E-B21EF07459B8Q40040761-3EDCFB98-6093-44E2-A7AE-82CF9AEB2818Q40103866-6CB05F93-EC30-42E6-A5F3-617A447C440BQ40984277-DE3ED1DC-6B23-4721-AA0F-4D418DE716B4Q41085075-DB69DDE1-B771-4B4B-876B-AFD49CDBFC64Q41750668-D9EF7809-DB3F-47C2-B712-DE71E93B212AQ44861189-5920F7F2-833D-4334-A108-04CC45DD38EFQ45305786-4B700193-C430-4DBA-93B5-DB6A42B3ECA3Q48196748-7DB14368-D596-464B-9341-AFE699AD1047Q49149817-931A9993-20E3-4784-9287-294B5427A512Q50609171-8960B3D1-FD42-41BD-99DF-A627DEEC121DQ53090167-731564BA-92E2-453F-AE4D-BC8F106BB9DF
P2860
Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cyclophosphamide, doxorubicin, ...... ear follow-up in 135 patients.
@en
Cyclophosphamide, doxorubicin, ...... ear follow-up in 135 patients.
@nl
type
label
Cyclophosphamide, doxorubicin, ...... ear follow-up in 135 patients.
@en
Cyclophosphamide, doxorubicin, ...... ear follow-up in 135 patients.
@nl
prefLabel
Cyclophosphamide, doxorubicin, ...... ear follow-up in 135 patients.
@en
Cyclophosphamide, doxorubicin, ...... ear follow-up in 135 patients.
@nl
P2093
P2860
P1476
Cyclophosphamide, doxorubicin, ...... ear follow-up in 135 patients.
@en
P2093
Hui-qiang Huang
Liang Wang
Yu-jing Zhang
Zhong-jun Xia
P2860
P2888
P304
P356
10.1007/S12185-012-1174-Y
P577
2012-09-16T00:00:00Z